GT Biopharma Inc Aktie News

FDA-Freigabe eines neuen IND für GTB-5550 beim multiplen Myelom (MM) im Rahmen eines von Ermittlern unterstützten Versuchsprotokolls (IST) Einleitung einer Phase‑1-Studie bei MM-Patienten abhängig vom Timing und Eingang nicht verwässernder Fördermittel Durchführung einer Phase‑1-Dosis-Eskalations-Basket-Studie mit GTB-5550 bei Patienten mit soliden Tumoren läuft weiterhin aktiv, mit einer Aktua...

SAN FRANCISCO, CALIFORNIA, 11. Sept. 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (das „Company“) (NASDAQ: GTBP), ein im klinischen Stadium tätiges Immunonkologie-Unternehmen, das sich auf die Entwicklung innovativer Therapeutika auf Basis der firmeneigenen TriKE®-Natural-Killer-(NK)-Zell-Engager-Plattform konzentriert, wird heute, am 11. September 2026, um 14:00 Uhr Eastern Time eine Live-Unter...

Phase-1-Studie zur Bewertung von GTB-3650 TriKE ® läuft weiterhin; ein Update wird für das 2. Hj. 2026 erwartet

Issued on behalf of GT Biopharma, Inc. (Nasdaq: GTBP) A clinical-stage immuno-oncology company has moved three drug candidates into human testing over time --- and most recently expanded into solid tumors --- while carrying a market value that remains modest relative to many clinical-stage oncology peers. SAN FRANCISCO, June 08, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary -- Most c...

Increased integration of artificial intelligence–based tools across the discovery and engineering of tumor-targeting engagers and multi-domain proteins to accelerate development while reducing developmental costs Reduces reliance on trial-and-error experimentation, shortens development timelines, and increases likelihood that pipeline candidates demonstrate robust binding and functional activit...

Phase 1 trial evaluating GTB-3650 TriKE ® remains ongoing, with additional updates anticipated in 2H 2026 Phase 1 basket trial evaluating GTB-5550 TriKE ® in multiple solid tumor types known to express B7-H3 initiated May 2026 with updates anticipated in 2H 2026 as enrollment progresses through dose escalation cohorts Cash balance as of March 31, 2026 of approximately $9 million anticipated to ...

GTB-5550 is now the 3rd TriKE ® to enter the clinic and an expansion into a broader solid tumor opportunity, with the Phase 1 trial likely to focus on prostate cancer patients during the dose escalation phase Company anticipates providing updates in 2H 2026 as enrollment progresses through dose escalation cohorts SAN FRANCISCO, CALIFORNIA, May 14, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (th...